Published in Clin Gastroenterol Hepatol on April 13, 2013
Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. Am J Gastroenterol (2016) 0.91
Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res (2015) 0.89
Mucosal healing and deep remission: what does it mean? World J Gastroenterol (2013) 0.87
Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing. Biomed Opt Express (2016) 0.81
Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective. Mol Cell Proteomics (2015) 0.78
Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein. Dig Dis Sci (2015) 0.78
Residual inflammation and ulcerative colitis in remission. Gastroenterol Hepatol (N Y) (2014) 0.78
Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis. Gastroenterol Res Pract (2015) 0.75
Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol (2016) 0.75
Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice. Exp Ther Med (2016) 0.75
Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc (2016) 0.75
Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol (2017) 0.75
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
A simple clinical colitis activity index. Gut (1998) 4.35
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Microscopic activity in ulcerative colitis: what does it mean? Gut (1991) 2.43
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol (2010) 2.07
Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis (2011) 1.97
Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis (2010) 1.74
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut (2005) 1.72
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology (2001) 1.71
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis (1966) 1.28
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis (2013) 1.27
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis (2012) 1.21
Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol (2008) 0.94
Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis (2009) 0.94
Treat the patient or treat the disease? Dig Dis (2012) 0.93
The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. Inflamm Bowel Dis (2004) 0.85
Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig Dis (2011) 0.78
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 3.43
Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis (2010) 3.09
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res (2002) 2.41
Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 2.06
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
Lipomatosis of the sciatic nerve secondary to compression by a desmoid tumor. Skeletal Radiol (2013) 2.03
Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis (2015) 1.98
Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus. Nat Med (2010) 1.76
Three brothers with dysphagia caused by eosinophilic esophagitis. Gastrointest Endosc (2005) 1.66
Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol (2012) 1.66
Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. Nucl Med Commun (2012) 1.52
Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol (2011) 1.51
Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol (2009) 1.42
Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy? Radiology (2008) 1.41
Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.40
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol (2014) 1.39
Good agreement between endoscopic findings and biopsy reports supports limited tissue sampling during pediatric colonoscopy. J Pediatr Gastroenterol Nutr (2014) 1.39
Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol (2003) 1.36
Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol (2003) 1.29
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis (2013) 1.27
Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev (2009) 1.20
Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol (2006) 1.14
Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A (2008) 1.12
Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med (2014) 1.11
Comment on Moshkovska et al. Inflamm Bowel Dis (2013) 1.07
In silico gene expression analysis--an overview. Mol Cancer (2007) 1.06
Pregnant patients suspected of having acute appendicitis: effect of MR imaging on negative laparotomy rate and appendiceal perforation rate. Radiology (2009) 1.06
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05
Best practices in diagnostic immunohistochemistry: spindle cell neoplasms of the gastrointestinal tract. Arch Pathol Lab Med (2009) 1.05
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut (2007) 1.05
Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis (2011) 1.02
Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 1.02
Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis (2014) 1.01
Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.99
The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol (2009) 0.97
Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol (2004) 0.97
Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol (2015) 0.97
Role of PET and combination PET/CT in the evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis (2009) 0.95
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95
Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc (2011) 0.94
Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis (2009) 0.94
Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung (2004) 0.93
A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol (2013) 0.93
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis (2013) 0.92
Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.91
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs (2008) 0.91
Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis (2011) 0.90
Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology (2009) 0.90
Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol (2013) 0.90
Villin immunohistochemistry is a reliable method for diagnosing microvillus inclusion disease. Am J Surg Pathol (2015) 0.90
Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis (2012) 0.89
CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol (2012) 0.89
Image guided core needle biopsy of musculoskeletal lesions: are nondiagnostic results clinically useful? Clin Orthop Relat Res (2013) 0.89
Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.88
Thyroid cancer and Crohn's disease: association or coincidence? Inflamm Bowel Dis (2006) 0.88
Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis (2016) 0.87
Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis (2011) 0.87
Efficacy of IV Buscopan as a muscle relaxant in CT colonography. Eur Radiol (2003) 0.87
Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis (2014) 0.86
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis (2004) 0.85
Colonic surveillance by CT colonography using axial images only. Eur Radiol (2004) 0.85
Documented compliance with inflammatory bowel disease quality measures is poor. Dig Dis Sci (2014) 0.84
Juvenile polyps: recurrence in patients with multiple and solitary polyps. Clin Gastroenterol Hepatol (2010) 0.84
Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in gastroenterology practice guidelines. Am J Gastroenterol (2013) 0.84
Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci (2009) 0.83
Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide. Inflamm Bowel Dis (2013) 0.83
Spectral Imaging with Scattered Light: From Early Cancer Detection to Cell Biology. IEEE J Sel Top Quantum Electron (2012) 0.83
Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev (2014) 0.83
Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases. Dig Dis Sci (2015) 0.83
Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep (2015) 0.83
Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One (2010) 0.82
Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis (2011) 0.82
Orthopaedic case of the month: ankle pain and swelling in a 23-year-old man. Clin Orthop Relat Res (2010) 0.82
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol (2012) 0.82
The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis (2014) 0.82
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81